India Boosts Biopharma Sector With Rs 10,000 Crore Investment

As part of the Union Budget 2026-27, the government has launched the Biopharma Shakti scheme with a substantial outlay of Rs 10,000 crore over five years. This initiative is designed to position India as a global biopharma hub, focusing specifically on the development of biologics, biosimilars, and advanced treatments for non-communicable diseases such as cancer, diabetes, and autoimmune disorders.

The budget also reflects a strong commitment to medical research, with the Indian Council of Medical Research (ICMR) receiving a 27% funding increase to Rs 4,000 crore. To support this growth, the government is prioritizing the training of 1.5 lakh multi-skilled caregivers and 1 lakh allied health professionals. These efforts are intended to build a robust workforce capable of meeting the evolving demands of the domestic and international healthcare markets.

Beyond research and infrastructure, the government has taken direct steps to lower the cost of care. Customs duty exemptions have been granted for 17 life-saving cancer drugs and extended to seven additional rare diseases. These measures provide critical financial relief to patients and their families. By combining research funding, workforce training, and duty exemptions, the government is creating a comprehensive framework to improve health outcomes and foster innovation in the Indian pharmaceutical sector.